ACM
BBIO icon

Aisling Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Aisling Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342M Sell
4,589,611
-500,000
-10% -$35M 72.48% 1
2026
Q1 		$378M Hold
5,089,611
– – 79.35% 1
2025
Q4 		$389M Sell
5,089,611
-1,000,000
-16% -$65.6M 81.29% 1
2025
Q3 		$316M Buy
6,089,611
+21,486
+0.4% +$1.05M 69.29% 1
2025
Q2 		$262M Hold
6,068,125
– – 72.85% 1
2025
Q1 		$210M Hold
6,068,125
– – 72.72% 1
2024
Q4 		$167M Hold
6,068,125
– – 59.08% 1
2024
Q3 		$154M Hold
6,068,125
– – 59.18% 1
2024
Q2 		$154M Hold
6,068,125
– – 66.52% 1
2024
Q1 		$188M Hold
6,068,125
– – 63.5% 1
2023
Q4 		$245M Hold
6,068,125
– – 73.07% 1
2023
Q3 		$160M Hold
6,068,125
– – 65.94% 1
2023
Q2 		$104M Hold
6,068,125
– – 51.13% 1
2023
Q1 		$101M Hold
6,068,125
– – 48.41% 1
2022
Q4 		$46.2M Hold
6,068,125
– – 30.53% 1
2022
Q3 		$60.3M Hold
6,068,125
– – 40.05% 1
2022
Q2 		$55.1M Hold
6,068,125
– – 39.31% 1
2022
Q1 		$61.6M Hold
6,068,125
– – 33.24% 1
2021
Q4 		$101M Hold
6,068,125
– – 35.71% 1
2021
Q3 		$284M Hold
6,068,125
– – 56.71% 1
2021
Q2 		$370M Hold
6,068,125
– – 59.23% 1
2021
Q1 		$374M Buy
6,068,125
+2,078,713
+52% +$136M 67.28% 1
2020
Q4 		$284M Hold
3,989,412
– – 48.72% 1
2020
Q3 		$150M Hold
3,989,412
– – 47.82% 1
2020
Q2 		$130M Hold
3,989,412
– – 49.65% 1
2020
Q1 		$116M Buy
3,989,412
+153,690
+4% +$4.77M 50.4% 1
2019
Q4 		$134M Hold
3,835,722
– – 51.51% 1
2019
Q3 		$82.4M Hold
3,835,722
– – 42.93% 1
2019
Q2 		$103M Buy
+3,835,722
New +$105M 44.18% 1

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aisling Capital Management's BBIO Position: Q2 2026 in Review

Aisling Capital Management reduced its BridgeBio Pharma (BBIO) stake by 9.8% in Q2 2026, selling an estimated $35M and leaving 4,589,611 shares worth $342M. The position accounts for 72.48% of the portfolio, ranked #1.

Aisling Capital Management first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $389M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Aisling Capital Management held 4,589,611 shares of BridgeBio Pharma worth $342M as of Q2 2026.
  • Aisling Capital Management sold 500,000 BridgeBio Pharma shares in Q2 2026, an estimated $35M.
  • BridgeBio Pharma made up 72.48% of Aisling Capital Management's portfolio in Q2 2026, its #1 holding.
  • Aisling Capital Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • Aisling Capital Management's BridgeBio Pharma position peaked at $389M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Aisling Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.